Endo Pharmaceuticals rated buy by Jefferies

Endo Pharmaceuticals Holdings Inc. was rated buy with a $33.00 price target, according to Jefferies & Co., Inc. analysts David H. Windley and Himanshu Rastogi, who said Endo's Lidoderm and Percocet/Endocet are on track relative to their forecast. Endo shares closed Thursday down $0.02, or 0.07%, at $27.03 on volume of 912,334 shares compared to a three-month trailing average of 811,452 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.